Capecitabine-associated cerebellar ataxia

Lam, Masha S. H.; Kaufman, Douglas A.; Russin, Michael P.

doi:10.2146/ajhp080094

Cited by 5 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,7,17,21–25 These patients presented with signs of cerebellar dysfunction, such as ataxia, dysarthria, dysmetria, dysdiadochokinesia or vertigo, alone or in combination. All patients were under adjuvant or palliative chemotherapy of colon cancer, 4,7,17,21–23 except one patient being treated for metastatic breast cancer. 24 The latency period from capecitabine initiation to cerebellar dysfunction development ranged from one week to several months, with symptomatic reversion after capecitabine discontinuation.…”

Section: Discussion and Review Of Literaturementioning

confidence: 99%

See 1 more Smart Citation

Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment

Godinho

Casa‐Nova

Mesquita

et al. 2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Capecitabine is a fluoropyrimidine commonly used in the treatment of colorectal cancer which may cause central nervous system toxicity, namely cerebellar dysfunction. Case report We describe a 77-year-old man undergoing adjuvant treatment of colon cancer with capecitabine and oxaliplatin who presented with acute cerebellar ataxia and encephalopathy that progressed to coma. Diagnosis of toxic encephalopathy was made after the exclusion of alternative causes of neurological dysfunction and complete resolution of clinical findings with permanent discontinuation of chemotherapy. Discussion When patients with cancer develop symptoms and signs of central nervous dysfunction, metabolic and infectious causes plus tumor involvement of central nervous system must be sought. However, chemotherapy may also cause toxicity to the central nervous system. Capecitabine is no exception, although cerebellar dysfunction is rarely reported. Conclusion Although rare, capecitabine-induced encephalopathy may be severe and physicians should be aware of this possible side effect.

show abstract

Section: Discussion and Review Of Literaturementioning

confidence: 99%

“…Although the latter may also cause CNS neurotoxicity, there are no published reports of cerebellar dysfunction, except in patients simultaneously treated with oxaliplatin and fluoropyrimidines. 7,21,25…”

Section: Discussion and Review Of Literaturementioning

confidence: 99%

Acute reversible toxic encephalopathy during capecitabine and oxaliplatin treatment

Godinho

Casa‐Nova

Mesquita

et al. 2017

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2009

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 23 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Antidiabetic Agents; 21 Contrast Agents; 22 Bone Conservation Agents; 23 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract